癌症免疫治疗——硅谷狂人也来抢夺盛宴!

2016-05-03 MedSci MedSci原创

当我们在国内还在争论癌症免疫治疗是否有效时,美国人已大踏步前进!不仅是医疗圈子在努力,如今美国硅谷富豪也不甘寂寞,争夺肿瘤免疫治疗的大蛋糕!Napster和facebook双料创始人——Sean Parker快速进入这一领域,成为硅谷中癌症免疫疗法明星人物,而且一象他的眼光都是正确的。Jeffrey Bluestone凭借总计1.25亿美元的捐款,Sean Parker成立了以自己名字命名

当我们在国内还在争论癌症免疫治疗是否有效时,美国人已大踏步前进!

不仅是医疗圈子在努力,如今美国硅谷富豪也不甘寂寞,争夺肿瘤免疫治疗的大蛋糕!Napster和facebook双料创始人——Sean Parker快速进入这一领域,成为硅谷中癌症免疫疗法明星人物,而且一象他的眼光都是正确的。


Jeffrey Bluestone

凭借总计1.25亿美元的捐款,Sean Parker成立了以自己名字命名的帕克癌症免疫疗法研究所(Parker’s Institute)。在组建团队上,他毫不吝啬,请来了加州大学旧金山分校的生物学家Jeffrey Bluestone(如上图)作为领头人。Jeffrey Bluestone在90年代的研究促成了其中一种癌症免疫疗法的诞生,是该领域非常著名的学者,拥有数十年的研究经验,发表过超过300篇同行评审论文。

在运营策略上,Parker声称要将学术研究和医药行业进行连接。该研究所携手业内总计37家合作伙伴,几乎能找到的皆在其中。从传统医药巨头辉瑞,到热门初创企业朱诺治疗公司(Juno Therapeutics),再到非盈利组织美国癌症研究协会。不开玩笑地说,帕克同学的策略是联合癌症免疫疗法行业中的几乎每个人。“帕克找了该领域的主要玩家,将最好的成员选出来,然后对他们说,我要给你钱让你玩到极致。”美国癌症协会首席医疗官奥提斯·布劳利说。他所在的机构是为数不多的没有与帕克研究所建立合作的组织之一。

今年1月28日,奥巴马签署备忘录启动抗癌“登月计划”,正式任命副总统拜登为该项计划领导人,目标是推动癌症预防与治疗。该备忘录指出,癌症研究正处于“重大突破”的前夜,而加速在该领域的进展对美国而言至关重要。拜登也曾表示,该计划想要的不是渐变,而是在攻克癌症上的巨大跃进。无疑,免疫工程是该项计划的重中之重。

帕克免疫治疗研究所三位顶尖科学家,都是免疫治疗领域的先锋人物:Carl June (left), Jedd Wolchok (center),  Jim Allison 图片来自Winni Wintermeyer for Fortune MagazineTech Entrepeneur Sean Parker (left) talks to Jeff Bluestone (center), CEO and president of the Parker Institute for Cancer Immunotherapy, during a retreatat the Meadowood resort in St. Helena, CA.Photo by Winni Wintermeyer for Fortune. April 4, 2016.Parker (left); Jeff Bluestone (center), CEO of PICI;  Wolchok.

繁荣时代

通过上市,免疫工程初创公司筹集了大量资金用于开展人体试验。

如今难以用言语形容癌症免疫疗法是多么火爆。2014年以来,这一领域的数家初创公司陆续成功上市(如下图表);今年年初,约翰霍普金斯医院成立了自己的免疫疗法研究中心,总投资1.25亿美元,其中包括来自亿万富翁、前纽约市长迈克尔·彭博的资金;免疫疗法还是副总统拜登10亿美元抗癌“登月计划”中的重点板块;同时,很多医药公司也迫不及待地将更多免疫疗法纳入自己的产品线中。


《连线》杂志甚至指出,在受欢迎程度上能与这项技术旗鼓相当的美国流行文化包括可颂甜甜圈、菲比小精灵、以及2005年后的Facebook。如此火爆,那么免疫工程究竟是个什么东东?

免疫工程:已知的“杀手”

人类免疫系统被称为大自然的“大规模杀伤性武器”。它拥有十余种主要细胞类型,其中包括多种T细胞。它会抵御从未见过的病毒,比如抑制癌症(尽管并非总是如此),而最主要的功能是避免伤及自己的身体组织。它甚至还有记忆功能,而这也是疫苗接种的依据。

100多年前,美国外科医生威廉·科莱注意到,有时候意外感染会让肿瘤消失。随后,科莱将链球菌培养基注入到癌症患者体内,发现在部分病例中出现了肿瘤收缩的状况。1893年发表的这一发现表明,免疫系统是可以对抗癌症的。但当时因为太多问题无法回答,癌症免疫疗法仍只是被当作一个失败的理念。

免疫工程时间线


美国前总统吉米·卡特卡特罹患黑色素瘤。他服用了一种叫做Pembrolizumab新药物后,癌症扩散得到一定程度上的控制。2014年,FDA批准其用于临床测试,该药物通过阻拦PD-1蛋白,从而使人体产生追杀癌症的T细胞。


美国前总统吉米·卡特卡特

然而,经过40多年的科学研究,研究者们终于开始了解肿瘤细胞和免疫系统对话的本质,并逐步绘制出了控制免疫系统与肿瘤互动方式的分子网络。在过去的几年里,基于这些洞见,医药公司和实验室开始研究修复免疫系统的行为。

在所有提议中,最极端的方法是改变T细胞内的基因指令,目前,通过TALENs或最新的CRISPR等基因编辑技术可以轻松做到。去年,基因编辑初创公司爱迪塔斯医药(Editas Medicine)和英特利亚治疗(Intellia Therapeutics)均与研发T细胞疗法的公司签署了合作协议。“这是一个完美的开始。”加利福尼亚大学旧金山分校研究人员杰弗里·布鲁斯通说,“免疫细胞是运转良好的机器,但我们可以让这种运转更加顺畅。”

这一来自英国剑桥大学的视频神奇地展示了T细胞击败癌症细胞的过程:

基于过去几十年的研究工作(以及与免疫学相关的诺贝尔奖成果),研究人员已经发现了很多重要细节,包括T细胞如何识别和杀灭入侵者等。透过显微镜,我们可以看到这些细胞会展现出类似于动物的行为:爬行,探查,然后抓住另一个细胞,向其注入中毒性颗粒。就像小机器人一样,T细胞具有四处移动的能力,能够同其他细胞对话,会释放毒物,可改变微环境,具有记忆功能,并可实现自我增殖。

去年,研究者们制造了一些未来派的新型T细胞。在注入特定药物的情况下,这些细胞才会发起靶向搜寻和杀灭行动。也就是说,这一特征可以让这些细胞在特定的时间和地点发起进攻,具备被“遥控”功能。 目前,这些细胞只在小鼠身上进行过测试。

另外一种新型T细胞被研究者们称为“谷歌高级搜索”,即只有在某种癌细胞被锁定两种不同的标记后,它才会发起攻击行动——相当于对敌对细胞采取双重确认。这些工作都至关重要,因为将T细胞靶向到肝、肺或脑的肿瘤是非常危险的。有些患者在试验阶段会因为T细胞的误杀而不幸身亡。

抢滩布局

癌症研究是高风险的,但就像所有高风险的事物一样,竞争也异常激烈。先看看下面一张近几年该领域的重大交易图表。


图中提及的赛莱克蒂斯(Cellectis)是一家成立于法国的生物技术公司,现总部位于美国曼哈顿东区,它的首个T细胞疗法在去年年底被制药公司辉瑞(Pfizer)和施维雅(Servier)所收购。该公司发明了一种名为TALENs的基因编辑方法,即通过活细胞中的DNA剪切和修复,进行癌症治疗。赛莱克蒂斯是从2011年开始研发这种疗法的。

赛莱克蒂斯开发的T细胞有着很广泛的应用。先前的疗法使用的是患者自己的细胞,但有的患者体内并没有足够的T细胞。有先见之明的赛莱克蒂斯决定利用基因编辑技术开发高度工程化细胞,但最终目的却很简单,即实现T细胞的“普遍”供应,但T细胞一般具有巨大的杀伤潜力,并不那么容易供应。因为问题在于,你不能将X先生的T细胞注入Y先生体内,否则这些细胞会把Y先生视为‘非自我’,并发起全力攻击。这样一来,患者就会陷入危险境地。


但如果T细胞经过了基因编辑技术处理,这种风险基本可以消除,而这也是所有人所希望的。目前,这项技术已经在超过300名患者身上进行了测试,效果显著,通常都是完全缓解。十余家制药公司和生物技术公司正致力于将这种疗法推向市场。

另值得关注的是,朱诺医疗在今年1月以1.25亿美元的价格收购专注于单T细胞DNA测序的波士顿公司AbVitro。现在,该公司正试图确定癌细胞中的活跃T细胞,并对其受体展开研究。朱诺医疗首席科学家海厄姆·列维茨基表示,原先需要7个月才能完成的实验现在只需要7天,而数据累积也越来越多,平均一次实验可产生100GB的信息。“很多事情都是技术驱动的。”他说,“这些问题的出现已经有一段时间了,但却无法找到答案。现在通过新技术,我们可以以前所未有的方式审视它们。”

今年3月,由百特国际 (Baxter International)分拆出来的新制药公司Baxalta宣布,总计投资超过 17 亿美元,将与基因编辑公司Precision Bio Sciences进行合作,专攻新兴的免疫治疗市场。今年1月,总部设在都柏林的制药公司Shire医疗宣布将以320亿美元的高价收购Baxalta公司,意在打造世界最大的罕见病制药公司。Baxalta雄心勃勃地表示将开发6种不同的免疫治疗药物,并预计首款药物将在明年进行临床试验。

为了应对来自同行日趋激烈的竞争,帕克研究院的策略是联合加州大学旧金山分校、加州大学洛杉矶分校、宾州大学、斯坦福大学、 MD安德森癌症中心和纪念斯隆-凯特琳癌症中心六家著名机构——这些机构的研究人员将一道全力研究三大问题:改造T细胞抗癌,寻找癌细胞的“开关”,以及发现会让癌细胞逃避免疫系统的检查点抑制剂。

不仅在研发方面,“帕克联盟”在临床试验方面合作也十分紧密。试想如果一家医药公司要测试一种罕见癌症的抗癌药物,在单一地点可能需要花费两年的时间,才能招募到足够多的病人。但在帕克研究所里,他们可以接触到六个地点的病人,而只需同一组人员来处理就行了。无疑,医药公司会喜欢这种方法,因为省去他们几个月的时间,不用来来回回争论。

甚至,“帕克联盟”的研究专利也是由一组律师解决。帕克研究所将尝试一种新的模式,即与研究人员所属的中心和大学共享一部分的专利。那这意味着,如果这些专利日后成了畅销药,那部分钱会用来继续资助研究所的研究工作。而且,新模式也解决了专利导致的研究问题:通常来说免疫疗法结合使用更好,但是很难让不同的公司都签同一个试验。这家公司有这个,那家公司有那个,两者永不聚,但如果帕克研究所拥有了全部相关免疫疗法的专利,之后和医药公司签署许可协议,问题就迎刃而解了。

然而现如今,参与免疫疗法研究的硅谷科技企业也绝不止帕克一家。去年,谷歌在麻省理工学院举办了两场有顶级免疫肿瘤学家和生物工程师参加的峰会,旨在确定免疫疗法的哪些部分可以“谷歌化”。与会人员表示,这家搜索巨头对迅速发展的新的肿瘤活检技术的研究非常关注。这些技术方法很可能将产生关于免疫系统细胞的大数据,比如,T细胞在肿瘤内的具体活动,以及T细胞如何对肿瘤产生影响等。但到目前为止,谷歌的生命科学部门Verily还没有正式公布,其在癌症免疫疗法方面的计划。

除了创业公司、科技巨头、癌症研究院和大型制药公司,医院也是积极参与方。著名的纽约西奈山医院从今年开始也将开始从事临床试验。患者会被注入一剂异常蛋白片段,而这些片段会训练T细胞攻击癌细胞。

Facebook前雇员、现担任西奈山医院及医学院下属实验室负责人的杰弗里·哈默巴赫尔对MIT TR表示,他正在与12名程序员一道研究T细胞,开发可解释患者癌细胞中DNA序列以及可从中预测杀伤性T细胞反应的软件。“有趣的是,我们向美国食品药品管理局(FDA)提交的并不是分子而是算法。”他说,“这或许是最早将程序输出作为疗法的案例之一。”

挽救癌症患者的生命,但只是一个开始

去年6月,12个月大的英国女孩蕾拉·理查德兹(见下图)已经处于病危状态。她是一名白血病患者,虽然接受过很多次化疗以及一次骨髓移植。但癌细胞仍在不断扩散。


女孩所在伦敦大奥蒙德街医院的一名医生给上面提到的赛莱克蒂斯公司打去了电话。“我们接到了一个电话。医生说,‘我们收治了一名缺乏T细胞的小女孩,现在已经无计可施。’”赛莱克蒂斯首席执行官安德烈·舒利卡说,“他们希望获得一瓶还在质量控制测试阶段制造的T细胞。”

医生希望将蕾拉作为一个“特例”,即通过未经临床试验的药物进行治疗。这是一场赌注,因为这种疗法仅在小鼠身上试验过。如果治疗失败,赛莱克蒂斯的股价和声誉将会大跌,而即便取得成功,该公司也可能会遭到监管机构调查。“一边是对生命的挽救,一边是对坏消息的规避。”舒利卡说。

去年11月,大奥蒙德街医院宣称蕾拉的病已经治愈。英国媒体竞相报道这则感人故事,对这名勇敢的女童和敢于作为的医生大加赞赏。铺天盖地的头版报道让赛莱克蒂斯的股价大幅飙升。两个星期后,制药公司辉瑞和施维雅宣布它们将以4000万美元的价格收购这一疗法。

虽然蕾拉案例的很多细节至今没有披露,一些癌症专家也表示工程化T细胞在其治疗中所发挥的作用仍不明朗,但她的康复无疑给很多人带来了希望,只是所有人都明白这只是个开始,并非意味着我们已经能够挽救癌症患者的生命。

超越癌症

在“免疫工程”以及免疫系统的控制和操作上的进步,将会给癌症治疗带来意想不到的突破。此外,这些进步还会催生用于治疗HIV和自身免疫疾病,如关节炎和多发性硬化症等。

去年3月,辉瑞任命林家扬担任公司旧金山生物技术部门的负责人。该部门负责癌症药物开发,最近又开始制造工程化T细胞。林家扬表示,他的公司早在媒体报道蕾拉事件之前就已同赛莱克蒂斯展开磋商,当时甚至都没有人料到她会被治愈。“这是一个巨大的惊喜。”他说。

林家扬表示,多年的科学研究工作最终结出果实,使得治疗产品成为一种可能。他认为,这种疗法将不仅仅局限于白血病,也不仅仅局限于癌症。“我们认为这个基本原理,即改造人体细胞,会有更广泛的寓意。”他说,“而免疫系统将会成为最便捷的工具,因为这些细胞可以移动和转移,并会发挥重要作用。”

研究人员早已对自身免疫紊乱展开研究,比如糖尿病、多发性硬化症和狼疮等。传染病也已进入T细胞工程师的视野。美国国家卫生研究院病毒学家、揭示HIV感染人体细胞机制的爱德华·贝格尔认为,对病毒进行永久阻断是可能的,即所谓的“功能性治愈”。今年2月,他表示,将会把基因改造的T细胞注入猴子体内,寻找并摧毁任何存在的免疫缺陷病毒的细胞。

真正的流程并不像理论这么简单。贝格尔认为,未来的路还很长,而且充满曲折。此外,大多数涉及工程化T细胞的规程都需要患者或猴子服用可临时杀灭自身T细胞的药物,而在此过程中,风险不可避免。但从目前的技术发展来看,这是一种非常激进的治疗方法。

尽管在治疗HIV方面已经取得进展,但方法还有待改进。即便是在治疗之后,病毒也会隐藏在人的体内,所以患者需要终生服用抗逆转录病毒药物。而通过免疫工程技术,则可能不需要。这让研究者们看到了一次治疗就可永久阻断病毒的可能性。

“癌症研究工作让我深受鼓舞。”贝格尔说,“我们可以借鉴白血病的治疗理念。通过免疫系统工程治疗其他疾病将是未来的一个主攻方向。就传染病而言,我认为HIV是一个最佳实验对象。如果你同HIV群体交谈,你会发现他们急需一种疗法,一种可以一劳永逸的疗法。”

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=85163, encodeId=cbe185163a3, content=学习了,很好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85164, encodeId=73ae85164e2, content=很好的,和哇, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85165, encodeId=b1f985165fa, content=真的不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85166, encodeId=9ee8851666c, content=很好的app, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84273, encodeId=87d2842e3b8, content=造福人类,永无止境, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Thu May 05 01:54:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84239, encodeId=72638423975, content=如果能够研究成果我为人类庆贺,为华人惋惜, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7e41690129, createdName=1de56ef3m97(暂无匿称), createdTime=Wed May 04 20:28:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84235, encodeId=dcfc84235a0, content=造福人类, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160426/IMG571F837F6E24A7354.jpg, createdBy=6f9e1717929, createdName=泉水叮咚, createdTime=Wed May 04 20:21:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83642, encodeId=e51f83642fa, content=医学前沿, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82f31713477, createdName=1deac008m83(暂无匿称), createdTime=Wed May 04 07:43:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83639, encodeId=4a728363927, content=这个研究有深度,眼光独到, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed May 04 07:14:00 CST 2016, time=2016-05-04, status=1, ipAttribution=)]
    2016-05-09 stead

    学习了,很好的

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=85163, encodeId=cbe185163a3, content=学习了,很好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85164, encodeId=73ae85164e2, content=很好的,和哇, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85165, encodeId=b1f985165fa, content=真的不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85166, encodeId=9ee8851666c, content=很好的app, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84273, encodeId=87d2842e3b8, content=造福人类,永无止境, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Thu May 05 01:54:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84239, encodeId=72638423975, content=如果能够研究成果我为人类庆贺,为华人惋惜, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7e41690129, createdName=1de56ef3m97(暂无匿称), createdTime=Wed May 04 20:28:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84235, encodeId=dcfc84235a0, content=造福人类, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160426/IMG571F837F6E24A7354.jpg, createdBy=6f9e1717929, createdName=泉水叮咚, createdTime=Wed May 04 20:21:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83642, encodeId=e51f83642fa, content=医学前沿, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82f31713477, createdName=1deac008m83(暂无匿称), createdTime=Wed May 04 07:43:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83639, encodeId=4a728363927, content=这个研究有深度,眼光独到, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed May 04 07:14:00 CST 2016, time=2016-05-04, status=1, ipAttribution=)]
    2016-05-09 stead

    很好的,和哇

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=85163, encodeId=cbe185163a3, content=学习了,很好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85164, encodeId=73ae85164e2, content=很好的,和哇, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85165, encodeId=b1f985165fa, content=真的不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85166, encodeId=9ee8851666c, content=很好的app, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84273, encodeId=87d2842e3b8, content=造福人类,永无止境, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Thu May 05 01:54:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84239, encodeId=72638423975, content=如果能够研究成果我为人类庆贺,为华人惋惜, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7e41690129, createdName=1de56ef3m97(暂无匿称), createdTime=Wed May 04 20:28:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84235, encodeId=dcfc84235a0, content=造福人类, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160426/IMG571F837F6E24A7354.jpg, createdBy=6f9e1717929, createdName=泉水叮咚, createdTime=Wed May 04 20:21:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83642, encodeId=e51f83642fa, content=医学前沿, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82f31713477, createdName=1deac008m83(暂无匿称), createdTime=Wed May 04 07:43:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83639, encodeId=4a728363927, content=这个研究有深度,眼光独到, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed May 04 07:14:00 CST 2016, time=2016-05-04, status=1, ipAttribution=)]
    2016-05-09 stead

    真的不错

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=85163, encodeId=cbe185163a3, content=学习了,很好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85164, encodeId=73ae85164e2, content=很好的,和哇, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85165, encodeId=b1f985165fa, content=真的不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85166, encodeId=9ee8851666c, content=很好的app, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84273, encodeId=87d2842e3b8, content=造福人类,永无止境, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Thu May 05 01:54:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84239, encodeId=72638423975, content=如果能够研究成果我为人类庆贺,为华人惋惜, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7e41690129, createdName=1de56ef3m97(暂无匿称), createdTime=Wed May 04 20:28:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84235, encodeId=dcfc84235a0, content=造福人类, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160426/IMG571F837F6E24A7354.jpg, createdBy=6f9e1717929, createdName=泉水叮咚, createdTime=Wed May 04 20:21:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83642, encodeId=e51f83642fa, content=医学前沿, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82f31713477, createdName=1deac008m83(暂无匿称), createdTime=Wed May 04 07:43:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83639, encodeId=4a728363927, content=这个研究有深度,眼光独到, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed May 04 07:14:00 CST 2016, time=2016-05-04, status=1, ipAttribution=)]
    2016-05-09 stead

    很好的app

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=85163, encodeId=cbe185163a3, content=学习了,很好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85164, encodeId=73ae85164e2, content=很好的,和哇, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85165, encodeId=b1f985165fa, content=真的不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85166, encodeId=9ee8851666c, content=很好的app, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84273, encodeId=87d2842e3b8, content=造福人类,永无止境, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Thu May 05 01:54:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84239, encodeId=72638423975, content=如果能够研究成果我为人类庆贺,为华人惋惜, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7e41690129, createdName=1de56ef3m97(暂无匿称), createdTime=Wed May 04 20:28:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84235, encodeId=dcfc84235a0, content=造福人类, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160426/IMG571F837F6E24A7354.jpg, createdBy=6f9e1717929, createdName=泉水叮咚, createdTime=Wed May 04 20:21:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83642, encodeId=e51f83642fa, content=医学前沿, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82f31713477, createdName=1deac008m83(暂无匿称), createdTime=Wed May 04 07:43:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83639, encodeId=4a728363927, content=这个研究有深度,眼光独到, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed May 04 07:14:00 CST 2016, time=2016-05-04, status=1, ipAttribution=)]
    2016-05-05 明崖

    造福人类,永无止境

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=85163, encodeId=cbe185163a3, content=学习了,很好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85164, encodeId=73ae85164e2, content=很好的,和哇, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85165, encodeId=b1f985165fa, content=真的不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85166, encodeId=9ee8851666c, content=很好的app, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84273, encodeId=87d2842e3b8, content=造福人类,永无止境, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Thu May 05 01:54:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84239, encodeId=72638423975, content=如果能够研究成果我为人类庆贺,为华人惋惜, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7e41690129, createdName=1de56ef3m97(暂无匿称), createdTime=Wed May 04 20:28:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84235, encodeId=dcfc84235a0, content=造福人类, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160426/IMG571F837F6E24A7354.jpg, createdBy=6f9e1717929, createdName=泉水叮咚, createdTime=Wed May 04 20:21:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83642, encodeId=e51f83642fa, content=医学前沿, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82f31713477, createdName=1deac008m83(暂无匿称), createdTime=Wed May 04 07:43:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83639, encodeId=4a728363927, content=这个研究有深度,眼光独到, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed May 04 07:14:00 CST 2016, time=2016-05-04, status=1, ipAttribution=)]
    2016-05-04 1de56ef3m97(暂无匿称)

    如果能够研究成果我为人类庆贺,为华人惋惜

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=85163, encodeId=cbe185163a3, content=学习了,很好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85164, encodeId=73ae85164e2, content=很好的,和哇, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85165, encodeId=b1f985165fa, content=真的不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85166, encodeId=9ee8851666c, content=很好的app, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84273, encodeId=87d2842e3b8, content=造福人类,永无止境, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Thu May 05 01:54:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84239, encodeId=72638423975, content=如果能够研究成果我为人类庆贺,为华人惋惜, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7e41690129, createdName=1de56ef3m97(暂无匿称), createdTime=Wed May 04 20:28:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84235, encodeId=dcfc84235a0, content=造福人类, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160426/IMG571F837F6E24A7354.jpg, createdBy=6f9e1717929, createdName=泉水叮咚, createdTime=Wed May 04 20:21:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83642, encodeId=e51f83642fa, content=医学前沿, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82f31713477, createdName=1deac008m83(暂无匿称), createdTime=Wed May 04 07:43:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83639, encodeId=4a728363927, content=这个研究有深度,眼光独到, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed May 04 07:14:00 CST 2016, time=2016-05-04, status=1, ipAttribution=)]
    2016-05-04 泉水叮咚

    造福人类

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=85163, encodeId=cbe185163a3, content=学习了,很好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85164, encodeId=73ae85164e2, content=很好的,和哇, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85165, encodeId=b1f985165fa, content=真的不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85166, encodeId=9ee8851666c, content=很好的app, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84273, encodeId=87d2842e3b8, content=造福人类,永无止境, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Thu May 05 01:54:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84239, encodeId=72638423975, content=如果能够研究成果我为人类庆贺,为华人惋惜, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7e41690129, createdName=1de56ef3m97(暂无匿称), createdTime=Wed May 04 20:28:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84235, encodeId=dcfc84235a0, content=造福人类, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160426/IMG571F837F6E24A7354.jpg, createdBy=6f9e1717929, createdName=泉水叮咚, createdTime=Wed May 04 20:21:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83642, encodeId=e51f83642fa, content=医学前沿, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82f31713477, createdName=1deac008m83(暂无匿称), createdTime=Wed May 04 07:43:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83639, encodeId=4a728363927, content=这个研究有深度,眼光独到, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed May 04 07:14:00 CST 2016, time=2016-05-04, status=1, ipAttribution=)]
    2016-05-04 1deac008m83(暂无匿称)

    医学前沿

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=85163, encodeId=cbe185163a3, content=学习了,很好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85164, encodeId=73ae85164e2, content=很好的,和哇, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85165, encodeId=b1f985165fa, content=真的不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85166, encodeId=9ee8851666c, content=很好的app, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:41:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84273, encodeId=87d2842e3b8, content=造福人类,永无止境, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Thu May 05 01:54:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84239, encodeId=72638423975, content=如果能够研究成果我为人类庆贺,为华人惋惜, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7e41690129, createdName=1de56ef3m97(暂无匿称), createdTime=Wed May 04 20:28:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84235, encodeId=dcfc84235a0, content=造福人类, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160426/IMG571F837F6E24A7354.jpg, createdBy=6f9e1717929, createdName=泉水叮咚, createdTime=Wed May 04 20:21:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83642, encodeId=e51f83642fa, content=医学前沿, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82f31713477, createdName=1deac008m83(暂无匿称), createdTime=Wed May 04 07:43:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83639, encodeId=4a728363927, content=这个研究有深度,眼光独到, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed May 04 07:14:00 CST 2016, time=2016-05-04, status=1, ipAttribution=)]
    2016-05-04 I come

    这个研究有深度,眼光独到

    0

相关资讯

IJC:月经不规则可能增加卵巢癌风险?

        最近一项研究表明,月经周期紊乱的女性晚年发生卵巢癌以及因卵巢癌死亡的风险更高。这项研究首次表明女性月经周期在非正常情况下变长或无月经与卵巢癌风险增加之间存在关联,同时对之前关于随着女性排卵总数增加,卵巢癌风险也逐渐增加的假说提出了挑战。 相关研究结果发表在国际学术期刊International Journal of Cancer上。

Nature:救命!科学家发现生长造血干细胞的新方法

麦克马斯特大学干细胞和癌症研究所(McMaster University's Stem Cell and Cancer Research Institute)研究人员在理解人类血液系统干细胞方面取得了重大进步,他们发现了一种关键蛋白质如何允许这些细胞更好的控制和再生。 这项研究最新发表于《Nature》期刊,阐明了一种被称为Musashi-2的蛋白质如何调节重要造血干细胞的功能和发育。

这五种生活习惯竟然能诱发癌症,简单的往往极难做到

导  语:   人们认为癌症离自己的生活很遥远,却不知道它如感冒般普遍,生活中一些坏的习惯很容易引起癌症的发生,究竟有哪些人容易得癌症呢?今天,小编就带您一起看看! 珍惜生命,远离癌症! 很多人一听到“癌症”这个词,立马谈“病”色变。美国华盛顿大学医学院病理和免疫学教授罗伯特·史莱伯发现,如果一些不良生活习惯维持10年,那你就会成为“癌症候选人”,因为在

液体活检开启癌症早期诊断大门

抓住血液中的肿瘤“尾巴” 液体活检开启癌症早期诊断大门 提取自血液样本的肿瘤DNA能够用于了解癌症,避免手术活检穿刺。 图片来源:Cultura RM/Alamy Stock Photo 肺部活检是一个侵入性的痛苦过程,对一位80岁的老太太来说尤其如此。但是通过穿刺性检查,肿瘤学家Geoffrey Oxnard给患者开出了一种相对应的靶向药物。经过治疗,患者的肿

过量食用培根会增加癌症风险

(图片摘自www.sciencealert.com) -最近,两家研究机构联合发表的一份报告称:加工肉制品--包括大家都喜爱的培根--会导致癌症发病率的上升。 就在去年,世界卫生组织发表了一篇相关的文章,文中称:食用加工肉制品会提高患结肠癌的风险。而最近的这份报告则加深了培根对癌症的影响。 这份由美国癌症研究所与世界癌症研究基金会联合发表的报告中显示:食用加工肉制品能够提高下腹部癌变的

我国研制出全球首台癌症早期检测设备 5分钟检测是否得癌症

图片来源:武汉晨报 杨佳峰 摄 中国一科研团队27日宣称,研制出全球首台适用于人体全身的临床全数字“正电子发射断层成像仪”(简称“PET”),可精准检测到最小尺寸病灶,大幅提前癌症发现时间。 该成果来源于华中科技大学首个国家重大科学仪器设备开发项目“超高分辨率PET的开发和应用”,由武汉光电国家实验室(筹)研究员、华中科技大学生命学院教授谢庆国带队完成。 PET是继超声